Transaction Details

Footnotes

Pursuant to the Agreement and Plan of Merger, as amended on April 20, 2025, by and among ACELYRIN, Inc., a Delaware corporation ("ACELYRIN") and Alumis Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement"), the shares of Common Stock were issued to the AyurMaya Fund (as defined below) in exchange for 9,334,735 shares of ACELYRIN common stock on the effective date of the merger contemplated by the Merger Agreement. | Reflects the estimated number of shares of Common Stock to be issued to the AyurMaya Fund (as defined below) pursuant to the Merger Agreement. The Reporting Persons will file an amendment to this Form 4 to the extent the actual number of shares of Common Stock issued differs in any material respect from the number reported in column (4). | The securities reported herein are held by AyurMaya Capital Management Fund, LP (the "AyurMaya Fund"). AyurMaya Capital Management Company, LP (the "Investment Manager"), a Delaware limited partnership, is the investment advisor to the AyurMaya Fund. Mr. David E. Goel ("Mr. Goel", and together with the Investment Manager, the "Reporting Persons"), serves as the managing member of AyurMaya Capital Management Company GP, LLC, the general partner of the Investment Manager. | The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.